Last €0.28 EUR
Change Today -0.003 / -1.07%
Volume 0.0
LYF On Other Exchanges
As of 2:08 AM 08/29/14 All times are local (Market data is delayed by at least 15 minutes).

ekf diagnostics holdings plc (LYF) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/22/14 - €0.44
52 Week Low
06/4/14 - €0.28
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

ekf diagnostics holdings plc (LYF) Related Businessweek News

No Related Businessweek News Found

ekf diagnostics holdings plc (LYF) Details

EKF Diagnostics Holdings plc is engaged in the design, development, manufacture, and sale of diagnostic instruments, reagents, and other ancillary products in the United Kingdom, the United States, Germany, Poland, Russia, Ireland, and Asia. The company offers near patient analyzers for the measurement of glucose, lactate, hemoglobin, hematocrit, and HbA1c. Its products include glycated hemoglobin analyzers, such as Quo-Test, Quo-Lab, and Biosen HbA1c analyzers for monitoring diabetes; hemoglobin analyzers consisting of Hemo Control and Hemo Vet, which are point of care devices to provide results for hemoglobin and hematocrit, as well as STAT-Site M Hgb, a hand-held device for blood screening programs; and glucose analyzers comprising Biosen C-Line and S-Line glucose and lactate analyzers, and Lactate Scout+, a hand-held lactate analyzer. The company also provides rapid testing services, including pregnancy tests, such as True20, QuPID, and QuStick for urine only or urine and serum pregnancy testing; and infectious diseases tests, such as H. Pylori, RELY Mono, RELY and Strep A, and QuStick for the detection of pathonogenic micro-organisms, such as bacteria, parasites, viruses, and fungi. In addition, it offers clinical chemistry reagents; and biomarker diagnostic kits used by researchers and clinicians, as well as molecular diagnostic test kits, which are focused on applications within oncological research. The company sells its products to GP surgeries, pharmacies, blood banks, sports clinics, hospitals, and laboratories through a network of distributors. EKF Diagnostics Holdings plc was founded in 1990 and is headquartered in Cardiff, the United Kingdom.

330 Employees
Last Reported Date: 02/26/14
Founded in 1990

ekf diagnostics holdings plc (LYF) Top Compensated Officers

Chief Executive Officer and Executive Directo...
Total Annual Compensation: 297.0K GBP
Executive Chairman
Total Annual Compensation: 45.0K GBP
Chief Financial Officer, Secretary and Execut...
Total Annual Compensation: 19.0K GBP
Chief Operating Officer and Executive Directo...
Total Annual Compensation: 214.0K GBP
Compensation as of Fiscal Year 2013.

ekf diagnostics holdings plc (LYF) Key Developments

EKF Diagnostics Holdings plc Announces Director Appointments

EKF Diagnostics Holdings plc announced the appointment of David Toohey and Doris-Ann Williams MBE to the Board as Non-Executive Directors with immediate effect. David Toohey has over 30 years of experience in international business, the last 20 of which have been in medical devices and the In Vitro Diagnostics industry. He is CEO and founder of Syncrophi Systems Ltd. Doris-Ann Williams has been Chief Executive of the British In Vitro Diagnostics Association since October 2001 and has more than 30 years of experience working in the IVD sector. She has had a variety of experience, initially in R&D and subsequently in commercial roles including international responsibilities. She is on the Editorial board of IVD Technology, sits on a number of steering groups including that of the Technology Strategy Board and is currently on the NHS Implementation Board for Innovation, Health and Wealth. She also works closely with European Diagnostic Manufacturers Association and other global IVD industry associations.

Ekf Diagnostics Holdings plc Announces Un-Audited Earnings Results for Six Months Ended June 30, 2014

EKF Diagnostics Holdings plc announced un-audited earnings results for six months ended June 30, 2014. For the period, unaudited revenues were 12% ahead of the same period last year at £16.7 million against £14.9 million a year ago, despite the negative impact of exchange rates of circa £1 million during the period. Unaudited adjusted EBITDA for the period was £2.2 million; a marginal increase on the previous year against £2.1 million a year ago, excluding the effect of exchange rates, adjusted EBITDA would have shown a c. 16% improvement on the same period last year.

EKF Diagnostics Holdings plc Signs Distribution Contract with Tianjin Multiclone Trading Company

EKF Diagnostics Holdings plc has signed a new distribution contract for Biosen C-Line, its glucose and lactate analyser, with Tianjin Multiclone Trading Company in China, which could significantly increase its installed user base. The initial contract is for 1,900 analysers worth approximately €4.0 million over a two and a half year period, commencing immediately. The end customer will also need to purchase consumables for the analyser, and it is anticipated that this could generate a further €2.0m of revenue over the same forecast period. Furthermore, whilst these initial revenue expectations are extremely pleasing, it is expected that these instruments will have a useful life of up to 10 years, which would significantly increase the consumables revenue for EKF.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
LYF:GR €0.28 EUR -0.003

LYF Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for LYF.
View Industry Companies

Industry Analysis


Industry Average

Valuation LYF Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 2.0x
Price/Book 1.6x
Price/Cash Flow 58.7x
TEV/Sales 3.2x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact EKF DIAGNOSTICS HOLDINGS PLC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at